- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03069066
Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment With Scoring Balloon Pre-dilatation (RIBS VI Scoring)
Prospective Study of Bioresorbable Vascular Scaffold Treatment With Scoring Balloon Pre-dilatation in Patients With In-stent Restenosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Treatment of patients with ISR remains a challenge. Currently both drug-eluting stents (DES) and drug-coated balloons (DCB) are considered as the strategies of choice in this setting. However, data on the value of BVS in patients with ISR is scarce. BVS are very effective to inhibit neointimal proliferation and they avoid the need of implanting a new permanent metal layer. Accordingly, currently, there is a major interest to elucidate the potential value of BVS in patients with ISR. The use of scoring balloon pre-dilatation has not been studied previously in this setting.
This prospective Spanish multicenter study will assess the clinical and angiographic outcome of patients with ISR treated with BVS with scoring balloon pre-dilatation. BVS will be implanted in selected patients (fulfilling inclusion and exclusion criteria) presenting with either BMS-ISR or DES-ISR. Care will be paid to ensure device optimization. Scoring balloon pre-dilatation is mandatory. Angiographic follow-up will be obtained at 6-9 months. A centralized angiographic corelab will be used to provide QCA measurements. Clinical follow-up will be also obtained at 1 year and then yearly. Clinical events will be adjudicated by an independent Clinical Event Committee.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08036
- Recruiting
- Hospital Clínic de Barcelona
-
Barcelona, Spain, 08025
- Recruiting
- Hospital de la Santa Creu i Sant Pau
-
Granada, Spain, 18014
- Recruiting
- Hospital Universitario Virgen de las Nieves
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28006
- Recruiting
- Hospital Universitario de La Princesa
-
-
A Coruña
-
Santiago de Compostela, A Coruña, Spain, 15006
- Recruiting
- Complexo Universitario Hospitalario de Santiago
-
-
Asturias
-
Oviedo, Asturias, Spain, 33006
- Recruiting
- Hospital Central de Asturias
-
-
Barcelona
-
L´Hospitalet de Llobregat, Barcelona, Spain, 08907
- Recruiting
- Hospital Universitari de Bellvitge
-
-
Madrid
-
Majadahonda, Madrid, Spain, 28222
- Recruiting
- Hospital Universitario Puerta de Hierro
-
-
Santa Cruz de Tenerife
-
San Cristobal de La Laguna, Santa Cruz de Tenerife, Spain, 38320
- Recruiting
- Hospital Universitario de Canarias
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
In-stent restenosis with ischemia. Signed Informed Consent IRB approval
INCLUSION CRITERIA:
PATIENT
- Age > 20 and < 85 years of age
- Acceptance of late angiographic evaluation
- Angina or objective evidence of ischemia
LESION
- ISR (>50% diameter stenosis on visual assessment)
- Previous stent location known
EXCLUSION CRITERIA:
PATIENT
- Inclusion in other clinical research protocol
- Allergy to antiplatelet agents
- Women in childbearing age
- Severe associated systemic diseases (including renal or liver failure) or diseases affecting life expectancy
- Recent myocardial infarction
- Time from index stent implantation < 1 month
- Anticipated difficulties for late angiographic evaluation
LESION
- Stent thrombosis or large thrombus within the stent
- Angiographic failure during initial stent implantation or persistence or large dissection.
- Severe tortuosity or calcification or major difficulties during previous stent implantation
- Vessel diameter < 2.25 mm (visual assessment)
- Stenosis outside stent stent edge (edge ISR are eligible)
- Very diffuse ISR (>30 mm in length)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BVS implantation in patients with ISR
BVS implantation in patients with ISR after scoring balloon pre-dilatation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Minimal lumen diameter as assessed by quantitative coronary angiography at late angiographic follow-up
Time Frame: angiographic follow-up at 6-9 months
|
This is a single arm study and results will be analyzed this arm.
However, the angiographic and clinical results will be also compared with those obtained in other arms of previous RIBS trials.
In particular results will be compared with those found in the RIBS VI study.
|
angiographic follow-up at 6-9 months
|
Combined clinical end-point (cardiac death, myocardial infarction and target vessel revascularization)
Time Frame: 1 year of clinical follow-up
|
This is a well-accepted outcome measure of individual clinical end-points. Definition of myocardial infarction is similar to that used in previous RIBS studies. The occurrence of ANY of these events will qualify for the combined event. That is, Cardiac death OR Myocardial Infarctio OR target vessel revascularization. (for the cobined end point the first event will be censored for each patient and other subsequent events will not apply). For time related statistics, the first event will be censored in the KM curves. In addition to that, the time and occurrence of each individual event will be also analyzed. The same strategy will be followed for the other combined clinical outcome measures that, again, are classically defined in this field. |
1 year of clinical follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Target-lesion failure (defined as cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization)
Time Frame: 1 year, 2 years, 3 years, 4 years, 5 years
|
This is a well-accepted outcome measure of individual clinical end-points
|
1 year, 2 years, 3 years, 4 years, 5 years
|
Cardiac death
Time Frame: 1 year, 2 years, 3 years, 4 years, 5 years
|
Individual clinical outcome
|
1 year, 2 years, 3 years, 4 years, 5 years
|
Total mortality
Time Frame: 1 year, 2 years, 3 years, 4 years, 5 years
|
Individual clinical outcome
|
1 year, 2 years, 3 years, 4 years, 5 years
|
Myocardial infarction
Time Frame: 1 year, 2 years, 3 years, 4 years, 5 years
|
Individual clinical outcome
|
1 year, 2 years, 3 years, 4 years, 5 years
|
Target vessel revascularization
Time Frame: 1 year, 2 years, 3 years, 4 years, 5 years
|
Individual clinical outcome
|
1 year, 2 years, 3 years, 4 years, 5 years
|
Target lesion revascularization
Time Frame: 1 year, 2 years, 3 years, 4 years, 5 years
|
Individual clinical outcome
|
1 year, 2 years, 3 years, 4 years, 5 years
|
Stent thrombosis
Time Frame: 1 year, 2 years, 3 years, 4 years, 5 years
|
Individual clinical outcome
|
1 year, 2 years, 3 years, 4 years, 5 years
|
Major bleeding
Time Frame: 1 year, 2 years, 3 years, 4 years, 5 years
|
Individual clinical outcome
|
1 year, 2 years, 3 years, 4 years, 5 years
|
Minimal lumen diameter
Time Frame: procedure
|
Acute angiographic parameter
|
procedure
|
Percent diameter stenosis
Time Frame: procedure
|
Acute angiographic parameter
|
procedure
|
Restenosis rate
Time Frame: 6-9 months
|
Late angiographic parameter
|
6-9 months
|
Percent diameter stenosis
Time Frame: 6-9 months
|
Late angiographic parameter
|
6-9 months
|
Late loss
Time Frame: 6-9 months
|
Change in minimal lumen diameter from the final procedure to the follow-up angiogram at 6-9 months.
Late angiographic parameter.
|
6-9 months
|
Loss index
Time Frame: 6-9 months
|
Late angiographic parameter
|
6-9 months
|
Acute gain
Time Frame: procedure
|
Change in the minimal lumen diameter from baseline to the final procedural angiogram.
Acute angiographic parameter
|
procedure
|
Net gain
Time Frame: 6-9 months
|
Is the difference between acute gain and late loss.
Late angiographic parameter
|
6-9 months
|
Combined clinical outcome measure (cardiac death, myocardial infarction, target lesion revascularization)
Time Frame: 1 year, 2 years, 3 years, 4 years, 5 years
|
This is a well-accepted outcome measure of individual clinical end-points. Definition of myocardial infarction is similar to that used in previous RIBS studies. The occurrence of ANY of these events will qualify for the combined event. That is, Cardiac death OR Myocardial Infarctio OR target vessel revascularization. (for the cobined end point the first event will be censored for each patient and other subsequent events will not apply). For time related statistics, the first event will be censored in the KM curves. In addition to that, the time and occurrence of each individual event will be also analyzed. The same strategy will be followed for the other combined clinical outcome measures that, again, are classically defined in this field. |
1 year, 2 years, 3 years, 4 years, 5 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Alfonso F, Zueco J, Cequier A, Mantilla R, Bethencourt A, Lopez-Minguez JR, Angel J, Auge JM, Gomez-Recio M, Moris C, Seabra-Gomes R, Perez-Vizcayno MJ, Macaya C; Restenosis Intra-stent: Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. J Am Coll Cardiol. 2003 Sep 3;42(5):796-805. doi: 10.1016/s0735-1097(03)00852-0.
- Alfonso F, Melgares R, Mainar V, Lezaun R, Vazquez N, Tascon J, Pomar F, Cequier A, Angel J, Perez-Vizcayno MJ, Sabate M, Banuelos C, Fernandez C, Garcia JM; Restensois Intra-stent: Ballon angioplasty versus elective Stenting (RIBS) Investigators. Therapeutic implications of in-stent restenosis located at the stent edge. Insights from the restenosis intra-stent balloon angioplasty versus elective stenting (RIBS) randomized trial. Eur Heart J. 2004 Oct;25(20):1829-35. doi: 10.1016/j.ehj.2004.07.019.
- Alfonso F, Auge JM, Zueco J, Bethencourt A, Lopez-Minguez JR, Hernandez JM, Bullones JA, Calvo I, Esplugas E, Perez-Vizcayno MJ, Moreno R, Fernandez C, Hernandez R, Gama-Ribeiro V; RIBS Investigators. Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol. 2005 Sep 6;46(5):756-60. doi: 10.1016/j.jacc.2005.05.050.
- Alfonso F, Perez-Vizcayno MJ, Gomez-Recio M, Insa L, Calvo I, Hernandez JM, Bullones JA, Hernandez R, Escaned J, Macaya C, Gama-Ribeiro V, Leitao-Marques A; Restenosis Intrastent: Balloon Angioplasty Versus Elective Stenting (RIBS) Investigators. Implications of the "watermelon seeding" phenomenon during coronary interventions for in-stent restenosis. Catheter Cardiovasc Interv. 2005 Dec;66(4):521-7. doi: 10.1002/ccd.20524.
- Alfonso F, Cequier A, Angel J, Marti V, Zueco J, Bethencourt A, Mantilla R, Lopez-Minguez JR, Gomez-Recio M, Moris C, Perez-Vizcayno MJ, Fernandez C, Macaya C, Seabra-Gomes R; Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) Investigators. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial. Am Heart J. 2006 Mar;151(3):681.e1-681.e9. doi: 10.1016/j.ahj.2005.10.014.
- Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, Lopez-Minguez JR, Angel J, Mantilla R, Moris C, Cequier A, Sabate M, Escaned J, Moreno R, Banuelos C, Suarez A, Macaya C; RIBS-II Investigators. A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial. J Am Coll Cardiol. 2006 Jun 6;47(11):2152-60. doi: 10.1016/j.jacc.2005.10.078.
- Alfonso F, Perez-Vizcayno MJ, Hernandez R, Fernandez C, Escaned J, Banuelos C, Bethencourt A, Lopez-Minguez JR, Angel J, Cequier A, Sabate M, Moris C, Zueco J, Seabra-Gomes R; Restenosis Intra-Stent: Balloon Angioplasty Versus Elective Stent Implantation (RIBS-I) and Restenosis Intra-Stent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) Investigators. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: results of a pooled analysis of two randomized studies. Catheter Cardiovasc Interv. 2008 Oct 1;72(4):459-67. doi: 10.1002/ccd.21694.
- Alfonso F, Perez-Vizcayno MJ, Hernandez R, Bethencourt A, Marti V, Lopez-Minguez JR, Angel J, Iniguez A, Moris C, Cequier A, Sabate M, Escaned J, Jimenez-Quevedo P, Banuelos C, Suarez A, Macaya C; RIBS-II Investigators. Long-term clinical benefit of sirolimus-eluting stents in patients with in-stent restenosis results of the RIBS-II (Restenosis Intra-stent: Balloon angioplasty vs. elective sirolimus-eluting Stenting) study. J Am Coll Cardiol. 2008 Nov 11;52(20):1621-7. doi: 10.1016/j.jacc.2008.08.025.
- Alfonso F, Perez-Vizcayno MJ, Dutary J, Zueco J, Cequier A, Garcia-Touchard A, Marti V, Lozano I, Angel J, Hernandez JM, Lopez-Minguez JR, Melgares R, Moreno R, Seidelberger B, Fernandez C, Hernandez R; RIBS-III Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]). JACC Cardiovasc Interv. 2012 Jul;5(7):728-37. doi: 10.1016/j.jcin.2012.03.017.
- Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia Del Blanco B, Seidelberger B, Iniguez A, Gomez-Recio M, Masotti M, Velazquez MT, Sanchis J, Garcia-Touchard A, Zueco J, Bethencourt A, Melgares R, Cequier A, Dominguez A, Mainar V, Lopez-Minguez JR, Moreu J, Marti V, Moreno R, Jimenez-Quevedo P, Gonzalo N, Fernandez C, Macaya C; RIBS V Study Investigators, under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent). J Am Coll Cardiol. 2014 Apr 15;63(14):1378-86. doi: 10.1016/j.jacc.2013.12.006. Epub 2014 Jan 8.
- Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia Del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, Rivero F, Masotti M, Zueco J, Cequier A, Moris C, Fernandez-Ortiz A, Escaned J, Jimenez-Quevedo P, Gonzalo N, Fernandez C, Macaya C; Restenosis Intra-stent: drug-eluting Balloon vs. everolimus-eluting Stent (RIBS IV) Study Investigators (under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology). Rationale and design of the RIBS IV randomised clinical trial (drug-eluting balloons versus everolimus-eluting stents for patients with drug-eluting stent restenosis). EuroIntervention. 2015 Jul;11(3):336-42. doi: 10.4244/EIJY14M09_07.
- Alfonso F, Perez-Vizcayno MJ, Cardenas A, Garcia del Blanco B, Garcia-Touchard A, Lopez-Minguez JR, Benedicto A, Masotti M, Zueco J, Iniguez A, Velazquez M, Moreno R, Mainar V, Dominguez A, Pomar F, Melgares R, Rivero F, Jimenez-Quevedo P, Gonzalo N, Fernandez C, Macaya C; RIBS IV Study Investigators (under auspices of Interventional Cardiology Working Group of Spanish Society of Cardiology). A Prospective Randomized Trial of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis of Drug-Eluting Stents: The RIBS IV Randomized Clinical Trial. J Am Coll Cardiol. 2015 Jul 7;66(1):23-33. doi: 10.1016/j.jacc.2015.04.063.
- Alfonso F, Cuesta J, Garcia Del Blanco B, Bosa F, Perez de Prado A, Masotti M, Trillo R, Rumoroso JR, Moreno R, Cequier A, Gutierrez H, Garcia Touchard A, Lopez-Minguez JR, Zueco J, Serra A, Velazquez M, Moris C, Bastante T, Garcia-Guimaraes M, Rivero F, Fernandez-Perez C; Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment with Scoring Balloon Pre-dilatation (RIBS VI 'Scoring') Study Investigators (under the auspices of the Interventional Cardiology Working Group of the Spanish Society of Cardiology). Scoring balloon predilation before bioresorbable vascular scaffold implantation in patients with in-stent restenosis: the RIBS VI 'scoring' study. Coron Artery Dis. 2021 Mar 1;32(2):96-104. doi: 10.1097/MCA.0000000000000904.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIBS VI scoring
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary In-stent Restenosis
-
Spanish Society of CardiologyAbbott Medical Devices; Terumo Medical Corporation; Fundación de Investigación... and other collaboratorsUnknownCoronary In-stent RestenosisSpain
-
Second Affiliated Hospital, School of Medicine,...West China Hospital; The Third Xiangya Hospital of Central South University; Shanghai... and other collaboratorsUnknownCoronary In-stent RestenosisChina
-
Shanghai MicroPort Medical (Group) Co., Ltd.Not yet recruitingCoronary Artery In-stent Restenosis
-
DK Medical Technology (Suzhou) Co., Ltd.Core Medical (Beijing) Co., Ltd.Active, not recruitingCoronary In-stent RestenosisChina
-
B. Braun Medical Inc.Infraredx; Bright Research PartnersWithdrawnCoronary Artery Restenosis | In-stent Restenosis | In-stent Coronary Artery Restenosis
-
Best Vascular, Inc.UnknownCoronary In-stent RestenosisUnited States
-
Assiut UniversityNot yet recruiting
-
Luzerner KantonsspitalUnknown
-
Fundación Médica para la Investigación y Desarrollo...Abbott Medical Devices; Hospital San Carlos, Madrid; B.Braun Surgical SAUnknown
-
Cordis CorporationCompletedIn-Stent RestenosisUnited States
Clinical Trials on Bioresorbable vascular scaffold. Absorb GT1 (Abbott)
-
Samsung Medical CenterUnknownAcute Coronary SyndromesKorea, Republic of
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
The University of New South WalesTerminatedIschemia | Arterial Occlusive Diseases | Peripheral Arterial Disease (PTANew Zealand, Australia, Netherlands
-
Ottawa Heart Institute Research CorporationWithdrawnCoronary Artery Disease | Diabetes Mellitus
-
Abbott Medical DevicesCompleted
-
San Giuseppe Moscati HospitalCompletedST Elevation Acute Myocardial InfarctionItaly
-
Azienda Ospedaliera Bolognini di Seriate BergamoUnknownST-elevation Myocardial Infarction (STEMI)Italy
-
Changi General HospitalCompletedCritical Limb IschemiaSingapore
-
Duk-Woo Park, MDCardioVascular Research Foundation, KoreaTerminatedCardiovascular Diseases | Coronary Artery Disease | Coronary Disease | Arterial Occlusive DiseasesKorea, Republic of
-
National Taiwan University HospitalUnknown